A Phase II investigator-led trial investigating AstraZeneca’s Fasenra (benralizumab) treating eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD) has ...
GlobalData on MSN4mon
NMPA approves AstraZeneca’s Fasenra for severe asthmaThe China National Medical Products Association (NMPA) has approved AstraZeneca's Fasenra (benralizumab) as a maintenance ...
Hosted on MSN3mon
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune DiseaseThe AZN filing seeks marketing authorization for Fasenra as an add-on treatment for adult patients with relapsing or refractory EGPA. This recommendation is based on data from the phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback